Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 467

1.

Improvement in prediction of antigenic epitopes using stacked generalisation: an ensemble approach.

Khanna D, Rana PS.

IET Syst Biol. 2020 Feb;14(1):1-7. doi: 10.1049/iet-syb.2018.5083.

PMID:
31931475
2.

Psychometric validation of the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU®) patient-reported outcome instrument.

Mouthon L, Poiraudeau S, Vernon M, Papadakis K, Perchenet L, Khanna D.

Arthritis Res Ther. 2020 Jan 6;22(1):3. doi: 10.1186/s13075-019-2087-4.

3.

HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry.

Gourh P, Safran SA, Alexander T, Boyden SE, Morgan ND, Shah AA, Mayes MD, Doumatey A, Bentley AR, Shriner D, Domsic RT, Medsger TA Jr, Ramos PS, Silver RM, Steen VD, Varga J, Hsu V, Saketkoo LA, Schiopu E, Khanna D, Gordon JK, Kron B, Criswell LA, Gladue H, Derk CT, Bernstein EJ, Bridges SL Jr, Shanmugam VK, Kolstad KD, Chung L, Kafaja S, Jan R, Trojanowski M, Goldberg A, Korman BD, Steinbach PJ, Chandrasekharappa SC, Mullikin JC, Adeyemo A, Rotimi C, Wigley FM, Kastner DL, Boin F, Remmers EF.

Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):552-562. doi: 10.1073/pnas.1906593116. Epub 2019 Dec 23.

4.

Fatigue and its Association with Social Participation, Functioning and Quality of Life in Systemic Sclerosis.

Murphy SL, Kratz AL, Whibley D, Poole JL, Khanna D.

Arthritis Care Res (Hoboken). 2019 Dec 16. doi: 10.1002/acr.24122. [Epub ahead of print]

PMID:
31841268
5.

A Multi-Centre Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis.

Hughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, Herrick AL, Khanna D, Matucci-Cerinic M, McKenzie L, Saketkoo LA, Gooberman-Hill R, Moore A.

Arthritis Care Res (Hoboken). 2019 Dec 16. doi: 10.1002/acr.24127. [Epub ahead of print]

PMID:
31841265
6.

Aetiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.

Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J.

Am J Respir Crit Care Med. 2019 Dec 16. doi: 10.1164/rccm.201903-0563CI. [Epub ahead of print]

PMID:
31841044
7.

Capillary Proliferation in Systemic-Sclerosis-Related Pulmonary Fibrosis: Association with Pulmonary Hypertension.

Seki A, Anklesaria Z, Saggar R, Dodson MW, Schwab K, Liu MC, Charan Ashana D, Miller WD, Vangala S, DerHovanessian A, Channick R, Shaikh F, Belperio JA, Weigt SS, Lynch JP, Ross DJ, Sullivan L, Khanna D, Shapiro SS, Sager J, Gargani L, Stanziola A, Bossone E, Schraufnagel DE, Fishbein G, Xu H, Fishbein MC, Wallace WD, Saggar R.

ACR Open Rheumatol. 2019 Mar 15;1(1):26-36. doi: 10.1002/acr2.1003. eCollection 2019 Mar.

8.

Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile.

Skaug B, Khanna D, Swindell WR, Hinchcliff ME, Frech TM, Steen VD, Hant FN, Gordon JK, Shah AA, Zhu L, Zheng WJ, Browning JL, Barron AMS, Wu M, Visvanathan S, Baum P, Franks JM, Whitfield ML, Shanmugam VK, Domsic RT, Castelino FV, Bernstein EJ, Wareing N, Lyons MA, Ying J, Charles J, Mayes MD, Assassi S.

Ann Rheum Dis. 2019 Nov 25. pii: annrheumdis-2019-215894. doi: 10.1136/annrheumdis-2019-215894. [Epub ahead of print]

PMID:
31767698
9.

Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?

Hughes M, Khanna D, Pauling JD.

Rheumatology (Oxford). 2019 Oct 31. pii: kez522. doi: 10.1093/rheumatology/kez522. [Epub ahead of print] No abstract available.

PMID:
31670800
10.

Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry.

Shanmugam VK, Frech TM, Steen VD, Hummers LK, Shah AA, Bernstein EJ, Khanna D, Gordon JK, Castelino FV, Chung L, Hant FN, Startup E, VanBuren JM, Evnin LB, Assassi S.

Clin Rheumatol. 2020 Jan;39(1):93-102. doi: 10.1007/s10067-019-04792-y. Epub 2019 Oct 30.

PMID:
31667644
11.

An Experimental Slope Method for a More Accurate Measurement of Relative Radiation Doses using Radiographic and Radiochromic Films and Its Application to Megavoltage Small-Field Dosimetry.

Holla R, Khanna D, Pillai BK, Jafar Ali KV, Renil Mon PS, Clinto CO, Ganesh T.

J Med Phys. 2019 Jul-Sep;44(3):145-155. doi: 10.4103/jmp.JMP_17_19.

12.

Classification of drug molecules for oxidative stress signalling pathway.

Verma N, Singh H, Khanna D, Rana PS, Bhadada SK.

IET Syst Biol. 2019 Oct;13(5):243-250. doi: 10.1049/iet-syb.2018.5078.

PMID:
31538958
13.

Reliability, construct validity and responsiveness to change of the PROMIS-29 in systemic sclerosis-associated interstitial lung disease.

Fisher CJ, Namas R, Seelman D, Jaafar S, Homer K, Wilhalme H, Young A, Nagaraja V, White ES, Schiopu E, Flaherty K, Khanna D.

Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):49-56. Epub 2019 Sep 4.

14.

A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.

Nagaraja V, Spino C, Bush E, Tsou PS, Domsic RT, Lafyatis R, Frech T, Gordon JK, Steen VD, Khanna D.

Arthritis Res Ther. 2019 Sep 3;21(1):202. doi: 10.1186/s13075-019-1979-7.

15.

Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease.

Kim GHJ, Tashkin DP, Lo P, Brown MS, Volkmann ER, Gjertson DW, Khanna D, Elashoff RM, Tseng CH, Roth MD, Goldin JG.

Arthritis Rheumatol. 2019 Aug 20. doi: 10.1002/art.41085. [Epub ahead of print]

PMID:
31430058
16.

Development and Pilot Testing of MyGoutCare: A Novel Web-Based Platform to Educate Patients With Gout.

Khanna P, Berrocal V, An L, Khanna D.

J Clin Rheumatol. 2019 Aug 12. doi: 10.1097/RHU.0000000000001126. [Epub ahead of print]

PMID:
31415480
17.

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6.

PMID:
31385462
18.

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Ann Rheum Dis. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5. Review.

19.

Computational Intelligence Technique for Prediction of Multiple Sclerosis Based on Serum Cytokines.

Goyal M, Khanna D, Rana PS, Khaibullin T, Martynova E, Rizvanov AA, Khaiboullina SF, Baranwal M.

Front Neurol. 2019 Jul 18;10:781. doi: 10.3389/fneur.2019.00781. eCollection 2019.

20.
21.

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.

Khanna D, Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, Berrocal V, Franks J, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schiopu E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Wang Y, Wood T, Allanore Y, Matucci-Cerinic M, Distler O, Singer O, Bush E, Fox DA, Furst DE.

Arthritis Rheumatol. 2020 Jan;72(1):125-136. doi: 10.1002/art.41055. Epub 2019 Dec 10.

PMID:
31342624
22.

Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.

Volkmann ER, Tashkin DP, Kuwana M, Li N, Roth MD, Charles J, Hant FN, Bogatkevich GS, Akter T, Kim G, Goldin J, Khanna D, Clements PJ, Furst DE, Elashoff RM, Silver RM, Assassi S.

Arthritis Rheumatol. 2019 Dec;71(12):2059-2067. doi: 10.1002/art.41020. Epub 2019 Nov 1.

PMID:
31233287
23.

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.

Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, Khanna D, Matucci-Cerinic M, de Oliveira Pena J, Pope JE, Distler O; EUSTAR Collaborators; EUSTAR Collaborators (numerical order of centres).

Ann Rheum Dis. 2019 Sep;78(9):1242-1248. doi: 10.1136/annrheumdis-2019-215145. Epub 2019 Jun 21.

24.

Knowledge, attitude, and practice about cervical cancer and its screening among community healthcare workers of Varanasi district, Uttar Pradesh, India.

Khanna D, Khargekar N, Budukh A.

J Family Med Prim Care. 2019 May;8(5):1715-1719. doi: 10.4103/jfmpc.jfmpc_143_19.

25.

Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis.

Jaafar S, Visovatti S, Young A, Huang S, Cronin P, Vummidi D, McLaughlin V, Khanna D.

Eur Respir J. 2019 Aug 22;54(2). pii: 1900586. doi: 10.1183/13993003.00586-2019. Print 2019 Aug.

PMID:
31196948
26.

Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study.

Kwakkenbos L, Thombs BD, Khanna D, Carrier ME, Baron M, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mayes MD, Mouthon L, Nielson WR, Poiraudeau S, Riggs R, Sauvé M, Wigley F, Hudson M, Bartlett SJ.

Rheumatology (Oxford). 2019 Jun 5. pii: kez234. doi: 10.1093/rheumatology/kez234. [Epub ahead of print] No abstract available.

PMID:
31168593
27.

Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features.

Hoffmann-Vold AM, Distler O, Murray B, Kowal-Bielecka O, Khanna D, Allanore Y; EUSTAR and SCTC collaborators.

RMD Open. 2019 Mar 4;5(1):e000826. doi: 10.1136/rmdopen-2018-000826. eCollection 2019.

28.

Health and Hygienic Parameters of Food Handlers and Sanitary Status of Food Establishments in a Medical College of Delhi.

Khanna D, Banerjee B, Tomar A, Gupta K, Pangtey R, Garg S.

Indian J Community Med. 2019 Jan-Mar;44(1):66-67. doi: 10.4103/ijcm.IJCM_248_18. No abstract available.

29.

5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.

Kahl DJ, Hutchings KM, Lisabeth EM, Haak AJ, Leipprandt JR, Dexheimer T, Khanna D, Tsou PS, Campbell PL, Fox DA, Wen B, Sun D, Bailie M, Neubig RR, Larsen SD.

J Med Chem. 2019 May 9;62(9):4350-4369. doi: 10.1021/acs.jmedchem.8b01772. Epub 2019 Apr 18.

30.

An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.

Baron M, Kahaleh B, Bernstein EJ, Chung L, Clements PJ, Denton C, Domsic RT, Ferdowsi N, Foeldvari I, Frech T, Gordon JK, Hudson M, Johnson SR, Khanna D, McMahan Z, Merkel PA, Narain S, Nikpour M, Pauling JD, Ross L, Valenzuela Vergara AM, Vacca A.

J Scleroderma Relat Disord. 2019 Feb;4(1):17-27. doi: 10.1177/2397198318783926. Epub 2018 Jul 18.

31.

Identification of Cysteine-Rich Angiogenic Inducer 61 as a Potential Antifibrotic and Proangiogenic Mediator in Scleroderma.

Tsou PS, Khanna D, Sawalha AH.

Arthritis Rheumatol. 2019 Aug;71(8):1350-1359. doi: 10.1002/art.40890. Epub 2019 Jun 12.

PMID:
30884213
32.

Management of systemic sclerosis-associated interstitial lung disease.

Roofeh D, Jaafar S, Vummidi D, Khanna D.

Curr Opin Rheumatol. 2019 May;31(3):241-249. doi: 10.1097/BOR.0000000000000592.

PMID:
30870216
33.

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.

Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, Matucci-Cerinic M, Pope JE, Denton CP, Khanna D, Distler O; EUSTAR Collaborators.

Ann Rheum Dis. 2019 May;78(5):648-656. doi: 10.1136/annrheumdis-2018-213455. Epub 2019 Mar 9.

34.

Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma.

Low AHL, Ng SA, Berrocal V, Brennan B, Chan G, Ng SC, Khanna D.

Int J Rheum Dis. 2019 Jun;22(6):1036-1040. doi: 10.1111/1756-185X.13523. Epub 2019 Mar 6.

35.

Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.

Volkmann ER, Tashkin DP, Sim M, Li N, Khanna D, Roth MD, Clements PJ, Hoffmann-Vold AM, Furst DE, Kim G, Goldin J, Elashoff RM.

J Rheumatol. 2019 Oct;46(10):1316-1325. doi: 10.3899/jrheum.180441. Epub 2019 Feb 15.

PMID:
30770517
36.

Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.

Young A, Vummidi D, Visovatti S, Homer K, Wilhalme H, White ES, Flaherty K, McLaughlin V, Khanna D.

Arthritis Rheumatol. 2019 Aug;71(8):1339-1349. doi: 10.1002/art.40862. Epub 2019 Jun 18.

PMID:
30762947
37.

Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma.

Tsou PS, Campbell P, Amin MA, Coit P, Miller S, Fox DA, Khanna D, Sawalha AH.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3695-3702. doi: 10.1073/pnas.1813006116. Epub 2019 Feb 12.

38.

Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.

Pauling JD, Frech TM, Hughes M, Gordon JK, Domsic RT, Anderson ME, Ingegnoli F, McHugh NJ, Johnson SR, Hudson M, Boin F, Ong VH, Matucci-Cerinic M, Altorok N, Scolnik M, Nikpour M, Shah A, Pope JE, Khanna D, Herrick AL.

J Scleroderma Relat Disord. 2018 Oct;3(3):249-252. doi: 10.1177/2397198318774307. Epub 2018 May 24.

39.

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Khanna D, Clements PJ, Volkmann ER, Wilhalme H, Tseng CH, Furst DE, Roth MD, Distler O, Tashkin DP.

Arthritis Res Ther. 2019 Jan 16;21(1):23. doi: 10.1186/s13075-019-1809-y.

40.

Study to Compare the Effect of Different Registration Methods on Patient Setup Uncertainties in Cone-beam Computed Tomography during Volumetric Modulated Arc Therapy for Breast Cancer Patients.

Mohandass P, Khanna D, Kumar TM, Thiyagaraj T, Saravanan C, Bhalla NK, Puri A.

J Med Phys. 2018 Oct-Dec;43(4):207-213. doi: 10.4103/jmp.JMP_67_18.

41.

Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Fung M, Baumgartner S, Perez-Ruiz F.

Arthritis Res Ther. 2019 Jan 7;21(1):8. doi: 10.1186/s13075-018-1788-4.

42.

Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology.

Butler EA, Baron M, Fogo AB, Frech T, Ghossein C, Hachulla E, Hoa S, Johnson SR, Khanna D, Mouthon L, Nikpour M, Proudman S, Steen V, Stern E, Varga J, Denton C, Hudson M; Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group.

Arthritis Rheumatol. 2019 Jun;71(6):964-971. doi: 10.1002/art.40809. Epub 2019 Apr 12.

PMID:
30614663
43.

Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities.

Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC.

QJM. 2019 Feb 1;112(2):81-93. doi: 10.1093/qjmed/hcy272. No abstract available.

PMID:
30605544
44.

Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities.

Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC.

Arthritis Rheumatol. 2019 Feb;71(2):182-195. doi: 10.1002/art.40769. Epub 2019 Jan 3. No abstract available.

PMID:
30604506
45.

Performance of Anti-Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting.

Homer KL, Warren J, Karayev D, Khanna PP, Young A, Nagaraja V, Metzger AL, Khanna D.

J Clin Rheumatol. 2018 Dec 20. doi: 10.1097/RHU.0000000000000971. [Epub ahead of print]

PMID:
30585996
46.

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.

Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M.

J Rheumatol. 2019 Jul;46(7):721-726. doi: 10.3899/jrheum.180478. Epub 2018 Dec 15.

PMID:
30554156
47.

Diagnosis of pulmonary hypertension.

Frost A, Badesch D, Gibbs JSR, Gopalan D, Khanna D, Manes A, Oudiz R, Satoh T, Torres F, Torbicki A.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801904. doi: 10.1183/13993003.01904-2018. Print 2019 Jan.

48.

Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium.

McMahan ZH, Frech T, Berrocal V, Lim D, Bruni C, Matucci-Cerinic M, Smith V, Melsens K, Proudman S, Zhang J, Mendoza F, Woods M, Khanna D.

J Rheumatol. 2019 Jan;46(1):78-84. doi: 10.3899/jrheum.180004. Epub 2018 Nov 15.

PMID:
30442827
49.

Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension.

Young A, Nagaraja V, Basilious M, Habib M, Townsend W, Gladue H, Badesch D, Gibbs JSR, Gopalan D, Manes A, Oudiz R, Satoh T, Torbicki A, Torres F, McLaughlin V, Khanna D.

Semin Arthritis Rheum. 2019 Jun;48(6):1059-1067. doi: 10.1016/j.semarthrit.2018.10.010. Epub 2018 Oct 14.

50.

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.

Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, Pinckney A, Furst DE, Clements PJ, Khanna D, Steen V, Schraufnagel DE, Arami S, Hsu V, Roth MD, Elashoff RM, Sullivan KM; SLS I and SLS II study groups.

Ann Rheum Dis. 2019 Jan;78(1):122-130. doi: 10.1136/annrheumdis-2018-213708. Epub 2018 Nov 8.

Supplemental Content

Loading ...
Support Center